跳转至内容
Merck
CN
  • Bone marrow stromal cells enhance the osteogenic properties of hydroxyapatite scaffolds by modulating the foreign body reaction.

Bone marrow stromal cells enhance the osteogenic properties of hydroxyapatite scaffolds by modulating the foreign body reaction.

Journal of tissue engineering and regenerative medicine (2012-07-12)
Gregory Tour, Mikael Wendel, Ion Tcacencu
摘要

We aimed to investigate the osteogenic properties of bone marrow stromal cell (BMSC)-loaded biomimetic constructs composed of hydroxyapatite (HA), with or without in vitro cell-derived extracellular matrix (HA-ECM), and to assess the cellular components of the elicited foreign body reaction. HA-ECM constructs were produced by adult rat dermal fibroblasts cultured on top of synthetic HA microparticles. Rat calvarial critical-sized defects (8 mm) were created and treated with the generated HA-ECM constructs or HA microparticles, alone or combined with green fluorescent protein (GFP)-expressing BMSCs. The new bone formation and the local cellular inflammatory response (macrophages, neutrophils, lymphocytes, eosinophils and PCNA-index) were assessed by histomorphometry and immunohistochemistry at 2 and 12 weeks postoperatively. In addition, the BMSCs' survival and engraftment were checked. The largest volume of the newly formed bone was found in defects treated with HA-ECM constructs combined with BMSCs (p < 0.05). Moreover, the implanted BMSCs modulated the local inflammatory response, demonstrated by either a significant increase (HA vs HA + BMSCs) or decrease (HA-ECM vs HA-ECM + BMSCs) of the inflammatory cell number. No donor BMSCs were detected at the site of implantation or in the host bone marrow at 2 or 12 weeks postoperatively. In conclusion, the treatment of critical-sized calvarial defects with the BMSC-loaded biomimetic constructs has significantly enhanced bone repair by modulating the foreign body reaction. Our findings highlight the implications of BMSCs in the regulation of the foreign body reaction triggered by tissue-engineered constructs, proving a higher efficiency for the BMSC combination therapy.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
氢氧化铵 溶液, ACS reagent, 28.0-30.0% NH3 basis
Sigma-Aldrich
氢氧化铵 溶液, 28% NH3 in H2O, ≥99.99% trace metals basis
Sigma-Aldrich
L -抗坏血酸, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L -抗坏血酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L -抗坏血酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
氢氧化铵 溶液, puriss., 30-33% NH3 in H2O
Sigma-Aldrich
L -抗坏血酸, 99%
Sigma-Aldrich
L -抗坏血酸, reagent grade, crystalline
Supelco
维生素C, Pharmaceutical Secondary Standard; Certified Reference Material
USP
抗坏血酸, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
氢氧化铵 溶液, puriss. p.a., reag. ISO, reag. Ph. Eur., ~25% NH3 basis
Sigma-Aldrich
L -抗坏血酸, ACS reagent, ≥99%
Supelco
L -抗坏血酸, analytical standard
Sigma-Aldrich
L -抗坏血酸, meets USP testing specifications
Sigma-Aldrich
氢氧化铵 溶液, BioUltra, ~1 M NH3 in H2O (T)
Sigma-Aldrich
L -抗坏血酸, reagent grade
Sigma-Aldrich
氢氧化铵 溶液, puriss., meets analytical specification of Ph. Eur., 25-30% NH3 basis
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
氢氧化铵 溶液, puriss. p.a. plus, ≥25% NH3 in H2O
Sigma-Aldrich
L -抗坏血酸, FCC, FG
Sigma-Aldrich
L -抗坏血酸, BioUltra, ≥99.5% (RT)
维生素C, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ≥99.0% (RT)
Supelco
L -抗坏血酸, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L -抗坏血酸, tested according to Ph. Eur.
Sigma-Aldrich
L -抗坏血酸, Vetec, reagent grade, 99%
Sigma-Aldrich
Anti-CCR7 antibody produced in rabbit, affinity isolated antibody